AAAAAA

   
Results: 1-15 |
Results: 15
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy
Authors: Harris, AL Reusch, P Barleon, B Hang, C Dobbs, N Marme, D
Citation: Al. Harris et al., Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy, CLIN CANC R, 7(7), 2001, pp. 1992-1997
Tumor angiogenesis: New approaches to cancer therapy
Authors: Marme, D
Citation: D. Marme, Tumor angiogenesis: New approaches to cancer therapy, ONKOLOGIE, 24, 2001, pp. 1-5
Raised serum vascular endothelial growth factor levels are associated withdestructive change in inflammatory arthritis
Authors: Ballara, S Taylor, PC Reusch, P Marme, D Feldmann, M Maini, RN Paleolog, EM
Citation: S. Ballara et al., Raised serum vascular endothelial growth factor levels are associated withdestructive change in inflammatory arthritis, ARTH RHEUM, 44(9), 2001, pp. 2055-2064
Expression of the vascular endothelial growth factor gene is inhibited by p73
Authors: Salimath, B Marme, D Finkenzeller, G
Citation: B. Salimath et al., Expression of the vascular endothelial growth factor gene is inhibited by p73, ONCOGENE, 19(31), 2000, pp. 3470-3476
Active interaction of human A375 melanoma cells with the lymphatics in vivo
Authors: Papoutsi, M Siemeister, G Weindel, K Tomarev, SI Kurz, H Schachtele, C Martiny-Baron, G Christ, B Marme, D Wilting, J
Citation: M. Papoutsi et al., Active interaction of human A375 melanoma cells with the lymphatics in vivo, HISTOCHEM C, 114(5), 2000, pp. 373-385
Induction of the blood-brain barrier marker neurothelin/HT7 in endothelialcells by a variety of tumors in chick embryos
Authors: Papoutsi, M Kurz, H Schachtele, C Marme, D Christ, B Prols, F Wilting, J
Citation: M. Papoutsi et al., Induction of the blood-brain barrier marker neurothelin/HT7 in endothelialcells by a variety of tumors in chick embryos, HISTOCHEM C, 113(2), 2000, pp. 105-113
Anthraquinones and betaenone derivatives from the sponge-associated fungusMicrosphaeropsis species: Novel inhibitors of protein kinases
Authors: Brauers, G Edrada, RA Ebel, R Proksch, P Wray, V Berg, A Grafe, U Schachtele, C Totzke, F Finkenzeller, G Marme, D Kraus, J Munchbach, M Michel, M Bringmann, G Schaumann, K
Citation: G. Brauers et al., Anthraquinones and betaenone derivatives from the sponge-associated fungusMicrosphaeropsis species: Novel inhibitors of protein kinases, J NAT PROD, 63(6), 2000, pp. 739-745
Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3proteins
Authors: Stoner, M Wang, F Wormke, M Nguyen, T Samudio, I Vyhlidal, C Marme, D Finkenzeller, G Safe, S
Citation: M. Stoner et al., Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3proteins, J BIOL CHEM, 275(30), 2000, pp. 22769-22779
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
Authors: Wood, JM Bold, G Buchdunger, E Cozens, R Ferrari, S Frei, J Hofmann, F Mestan, J Mett, H O'Reilly, T Persohn, E Rosel, J Schnell, C Stover, D Theuer, A Towbin, H Wenger, F Woods-Cook, K Menrad, A Siemeister, G Schirner, M Thierauch, KH Schneider, MR Drevs, J Martiny-Baron, G Totzke, F Marme, D
Citation: Jm. Wood et al., PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, CANCER RES, 60(8), 2000, pp. 2178-2189
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and flood flow in a murine renal cell carcinoma model
Authors: Drevs, J Hofmann, I Hugenschmidt, H Wittig, C Madjar, H Muller, M Wood, J Martiny-Baron, G Unger, C Marme, D
Citation: J. Drevs et al., Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and flood flow in a murine renal cell carcinoma model, CANCER RES, 60(17), 2000, pp. 4819-4824
Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro
Authors: Benzinger, P Martiny-Baron, G Reusch, P Siemeister, G Kley, JT Marme, D Unger, C Massing, U
Citation: P. Benzinger et al., Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro, BBA-BIOMEMB, 1466(1-2), 2000, pp. 71-78
Inhibition of VEGF receptor tyrosine kinase
Authors: Siemeister, G Menrad, A Schirner, M Thierauch, KH Schneider, MR Martiny-Baron, G Marme, D Bold, G Rosel, J Wood, JM
Citation: G. Siemeister et al., Inhibition of VEGF receptor tyrosine kinase, ANGIOGENESIS IN HEALTH AND DISEASE, 2000, pp. 339-348
Tumor angiogenesis: molecular facts and therapeutic opportunities
Authors: Marme, D
Citation: D. Marme, Tumor angiogenesis: molecular facts and therapeutic opportunities, CHIRURG, 70(1), 1999, pp. 31-35
Two independent mechanisms essential for tumor angiogenesis: Inhibition ofhuman melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway
Authors: Siemeister, G Schirner, M Weindel, K Reusch, P Menrad, A Marme, D Martiny-Baron, G
Citation: G. Siemeister et al., Two independent mechanisms essential for tumor angiogenesis: Inhibition ofhuman melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway, CANCER RES, 59(13), 1999, pp. 3185-3191
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
Authors: Kraft, A Weindel, K Ochs, A Marth, C Zmija, J Schumacher, P Unger, C Marme, D Gastl, G
Citation: A. Kraft et al., Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease, CANCER, 85(1), 1999, pp. 178-187
Risultati: 1-15 |